A Phase I Study of TQH2722 Injection to Evaluate the Safety, Tolerability, Pharmacokinetics, Efficacy and Immunogenicity in Healthy Adult Subjects
Latest Information Update: 07 Jun 2024
At a glance
- Drugs TQH 2722 (Primary)
- Indications Atopic dermatitis
- Focus Adverse reactions
- Sponsors Chia Tai Tianqing Pharmaceutical Group; Nanjing Shunxin Pharmaceutical
Most Recent Events
- 15 Jun 2022 New trial record